1 recruiting, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow Hyperlipoproteinemia Type V: new trials by email Literature Review of Hyperlipoproteinemia Type V trials Research Report on Hyperlipoproteinemia Type V
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| Study to Evaluate the Safety and PK of UI018 administration of UI018, co-administration of UIC201806 and UIC201602 - Hyperlipemia, Mixed | Phase 1 | Unknown | Korea United Pharm. Inc. | 44 | 2021-09-06 | 2021-12-21 |
Dyslipidemias (1) · Homozygous Familial Hypercholesterolemia (1) · Hypercholesterolemia (1) · Hypertriglyceridemia (1) · Lipid Metabolism Disorders (1) · Metabolic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hyperlipidemias (2) · Hyperlipoproteinemias (2) · Lipid Metabolism, Inborn Errors (2) · Metabolism, Inborn Errors (2) · Nutritional and Metabolic Diseases (2) · Dyslipidemias (1) · Hyperlipoproteinemia Type II (1) · Hypertriglyceridemia (1) · Lipid Metabolism Disorders (1) · Metabolic Diseases (1)
CRISPR Therapeutics AG (1) · Korea United Pharm. Inc. (1)
Australia (1) · New Zealand (1) · South Korea (1) · United Kingdom (1) · United States (1)
Injin Jang, Dr. (1)